Endocrine_therapy_for_desmoid_tumors._Two_female_patients_with_desmoid_tumors_(aggressive_fibromatosis)_showed_tumor_regression_after_endocrine_therapy._In_one_patient,_tumor_response_to_tamoxifen_has_been_maintained_over_several_years_of_treatment._In_the_second_patient,_who_had_inoperable_mesenteric_fibromatosis,_the_tumor_progressed_on_tamoxifen_but_regressed_after_treatment_with_Zoladex_(goserelin_acetate,_ICI,_Melbourne,_Australia)_and_medroxyprogesterone_acetate_(MPA)._To_the_authors'_knowledge_this_is_the_first_report_of_the_use_of_Zoladex_in_the_treatment_of_desmoid_tumors._This_review_of_the_literature_reveals_that_the_biology_of_this_disease_is_related_to_the_endogenous_hormonal_environment_and_that_estrogen_receptors_have_been_documented_in_desmoid_tumors._Thirty-five_cases_are_identified_where_endocrine_agents_have_been_employed,_with_a_response_rate_of_51%._Furthermore,_tumors_may_respond_to_second-line_hormonal_therapy_after_failing_to_respond_to_initial_endocrine_treatment._Endocrine_treatments_have_also_been_used_in_other_disorders_of_fibroblastic_origin._The_authors_recommend_that_endocrine_treatment_be_employed_in_inoperable_desmoid_tumors_or_where_there_has_been_postsurgical_recurrence._In_addition,_the_role_for_endocrine_therapy_in_other_soft_tissue_neoplasms_should_be_determined.